Remy Cointreau, Pernod Ricard shares hit by China probe of EU brandy
By Steve Goldstein
Shares in leading French makers of spirits plunged on Friday in wake of a Chinese investigation.
Remy Cointreau (FR:RCO) shares plunged 11% and Pernod Ricard stock (FR:RI) fell 5%, after China launched an anti-dumping investigation into brandy imported from the European Union.
According to JPMorgan, Remy generates about 30% of its profit from China, and Pernod generates about 20%.
"Limited info on what the results from such actions could be, butworst case scenario could be of increased tariffs on all EU Brandy, which could result in lower volumes and/or margins in the region," said Olivia Petronilho of JPMorgan in a note.
LVMH Moet Hennessy (FR:MC), whose wine and spirits account for about a tenth of its revenue, saw its stock fall by 2%.
The announcement by China follows the EU probe into China's electric vehicle makers.
The China Ministry of Commerce said it was responding to a complaint made by the domestic brandy industry.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-05-24 0703ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?